Lincoln Pharmaceuticals (531633) Q2 24/25 earnings summary

Executive summary

• Total income for the quarter ended September 30, 2024, was ₹17,119.11 lakhs, up from ₹15,769.10 lakhs in the same quarter last year.

• Net profit for the quarter was ₹2,633.03 lakhs, compared to ₹2,367.17 lakhs year-over-year.

• Financial results were reviewed by the audit committee and approved by the board on November 14, 2024.

Financial highlights

• Revenue from operations for the quarter was ₹16,121.35 lakhs, up from ₹14,728.18 lakhs year-over-year.

• Total expenses for the quarter were ₹13,640.79 lakhs, compared to ₹12,821.31 lakhs in the same period last year.

• Earnings per share (EPS) for the quarter stood at ₹13.15 (basic and diluted), up from ₹11.82 year-over-year.

• Total comprehensive income for the quarter was ₹2,634.56 lakhs, compared to ₹2,368.70 lakhs last year.

Outlook and guidance

• Results reflect continued growth in the pharmaceutical business segment.